Ezrin assay method for the in vitro diagnosis of colorectal cancer

Patent metadata

Field	Value
Publication number	US-9890196-B2
Application number	US-201213712340-A
Country	US
Kind code	B2
Filing date	Dec 12, 2012
Priority date	Jul 19, 2007
Publication date	Feb 13, 2018
Grant date	Feb 13, 2018

Abstract

A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.

First claim

The invention claimed is:

1. A peptide comprising an amino acid sequence having at least 85% sequence identity with the epitope of SEQ ID No.4+SEQ ID No.5 or SEQ ID No.6+SEQ ID No.7, wherein (i) the peptide has no more than 20 amino acid residues between SEQ ID No.4 and SEQ ID No.5 or between SEQ ID No.6 and SEQ ID No.7, and (ii) the peptide has no more than 10 additional amino acid residues on each side of the amino acid sequence.

2. The peptide of claim 1 , wherein the amino acid sequence has at least 90% sequence identity with the epitope of SEQ ID No.4+SEQ ID No5 or SEQ ID No.6+SEQ ID No.7.

3. The peptide of claim 1 , wherein the peptide comprises the epitope of SEQ ID No.4+SEQ ID No.5.

4. The peptide of claim 1 , wherein the peptide comprises the epitope of SEQ ID No.6+SEQ ID No.7.

5. A peptide comprising the epitope of SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7, or SEQ ID No.8, having at least one and no more than two heterologous amino acid additions, conservative substitutions, or internal deletions as compared with Swiss Prot No. P15311, wherein (i) the peptide has no more than 20 amino acid residues between SEQ ID No.4 and SEQ ID No.5 or between SEQ ID No.6 and SEQ ID No.7 when present in the peptide, and (ii) the peptide has no more than 10 additional amino acid residues on each side of the epitope.

6. The peptide of claim 5 , wherein the peptide has at least one and no more than two conservative amino acid substitutions.

7. The peptide of claim 5 , wherein the peptide has at least one and no more than two heterologous amino acid additions.

8. The peptide of claim 5 , wherein the peptide has at least one and no more than two internal amino acid deletions.

9. A peptide comprising the amino acid sequence of SEQ ID No.2, SEQ ID No.3, or SEQ ID No.8, having at least one and no more than two heterologous amino acid additions, conservative substitutions, or internal deletions as compared with Swiss Prot No. P15311, wherein the peptide has no more than 10 additional amino acid residues on each side of the amino acid sequence.

10. A peptide comprising the amino acid sequence of SEQ ID No.1, having at least one and no more than two heterologous amino acid additions or conservative substitutions as compared with Swiss Prot No. P15311, wherein the peptide has no more than the 10 additional amino acid residues on each side of the amino acid sequence.

11. The peptide of claim 9 , comprising the amino acid sequence of SEQ ID No.2, having the at least one and no more than two heterologous amino acid additions, conservative substitutions, or internal deletions as compared with Swiss Prot No. P15311, wherein the peptide has no more than the 10 additional amino acid residues on each side of the amino acid sequence.

12. The peptide of claim 9 , comprising the amino acid sequence of SEQ ID No.3, having the at least one and no more than two heterologous amino acid additions, conservative substitutions, or internal deletions as compared with Swiss Prot No. P15311, wherein the peptide has no more than the 10 additional amino acid residues on each side of the amino acid sequence.

13. The peptide of claim 9 , comprising the amino acid sequence of SEQ ID No.8, having the at least one and no more than two heterologous amino acid additions, conservative substitutions, or internal deletions as compared with Swiss Prot No. P15311, wherein the peptide has no more than the 10 additional amino acid residues on each side of the amino acid sequence.

Assignees

• Biomerieux Sa
• Centre Nat Rech Scient
• Inst Curie
• Centre Nationale De Recherche Scient

Inventors

• Ataman Onal Yasemin
• Busseret Sandrine
• Charrier Jean Philippe
• Choquet Kastylevsky Genevieve

Classifications

• G01N33/57535 Primary

  of the large intestine, e.g. colon, rectum or anus · CPC title

• G01N33/5759 Primary

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N2333/705

  Assays involving receptors, cell surface antigens or cell surface determinants · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• G01N33/57419

  Physics · mapped topic